RecruitingNCT04442711
Cohort of IPF Patients Experiencing an Exacerbation
Pulmonary Fibrosis Biomarkers During Exacerbation
Sponsor
University Hospital, Gentofte, Copenhagen
Enrollment
50 participants
Start Date
Jun 13, 2020
Study Type
OBSERVATIONAL
Conditions
Summary
Extension of the PFBIO cohort which includes patients with newly diagnosed idiopathic pulmonary fibrosis (IPF) for longitudinal follow-up for up to 5 years. In the PFBIO-EXA extension, patients are included if they experience an exacerbation, or other increase in respiratory symptoms requiring hospital admission, for further collection of clinical and biological data.
Eligibility
Min Age: 18 Years
Inclusion Criteria3
- Admitted with an increase in respiratory symptoms
- Already included in PFBIO or included simultaneously in PFBIO and PFBIO-EXA
- Age at least 18 years
Exclusion Criteria1
- Unable to provide informed consent
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT04442711
Related Trials
Senicapoc in Patients With Worsening Fibrotic Interstitial Lung Disease
NCT067141235 locations
WISPer: Evaluation of MTX-463 in Participants With Idiopathic Pulmonary Fibrosis (IPF)
NCT0696780569 locations
A Study in People With Idiopathic Pulmonary Fibrosis to Test Whether Pirfenidone Influences the Amount of BI 1015550 in the Blood
NCT062415603 locations
A Follow-up Study to Test Long-term Treatment With Nerandomilast in People With Pulmonary Fibrosis Who Took Part in a Previous Study With Nerandomilast
NCT06238622371 locations
A Study to Find Out Whether BI 765423 Has an Effect on Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF) With or Without Standard Treatment
NCT0703652347 locations